Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation
Nätkin, Reetta; Pennanen, Pasi; Syvälä, Heimo; Bläuer, Merja; Kesseli, Juha; Tammela, Teuvo L.J.; Nykter, Matti; Murtola, Teemu J. (2023-02)
Nätkin, Reetta
Pennanen, Pasi
Syvälä, Heimo
Bläuer, Merja
Kesseli, Juha
Tammela, Teuvo L.J.
Nykter, Matti
Murtola, Teemu J.
02 / 2023
e0281645
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202304123618
https://urn.fi/URN:NBN:fi:tuni-202304123618
Kuvaus
Peer reviewed
Tiivistelmä
Androgen deprivation therapy is the cornerstone treatment of advanced prostate cancer. Eventually prostate cancer cells overcome androgen deprivation therapy, giving rise to castration resistant prostate cancer (CRPC) characterized by increased androgen receptor (AR) activity. Understanding the cellular mechanisms leading to CRPC is needed for development of novel treatments. We used long-term cell cultures to model CRPC; a testosterone-dependent cell line (VCaP-T) and cell line adapted to grow in low testosterone (VCaP-CT). These were used to uncover persistent and adaptive responses to testosterone level. RNA was sequenced to study AR-regulated genes. Expression level changed due to testosterone depletion in 418 genes in VCaP-T (AR-associated genes). To evaluate significance for CRPC growth, we compared which of them were adaptive i.e., restored expression level in VCaP-CT. Adaptive genes were enriched to steroid metabolism, immune response and lipid metabolism. The Cancer Genome Atlas Prostate Adenocarcinoma data were used to assess the association with cancer aggressiveness and progression-free survival. Expressions of 47 AR-associated or association gaining genes were statistically significant markers for progression-free survival. These included genes related to immune response, adhesion and transport. Taken together, we identified and clinically validated multiple genes being linked with progression of prostate cancer and propose several novel risk genes. Possible use as biomarkers or therapeutic targets should be studied further.
Kokoelmat
- TUNICRIS-julkaisut [18531]